Mesynthes

Mesynthes' products are based on its proprietary Endoform technology platform. In vitro and in vivo models demonstrate that Endoform™ leads to quantitatively superior blood vessel ingrowth into the healing tissue which is known to improve the quality and rate of tissue regeneration and reduce infection and implant failure.

It also has excellent physical properties and improved safety. Endoform is  strong, safe and rich in fibrillar and adhesive proteins, glycosaminoglycans and growth factors, and is immunologically quiet.

Endoform provides immediate support and structure to damaged tissues,  allowing cells to repopulate the area and synthesize new matrix. Unlike other products, it is not chemically cross-linked and it includes important minor components of the extracellular matrix, which means Endoform presents native structure, signals and substrates to assist the process of tissue regeneration. Over time it is completely integrated, remodeled and replaced by the patient's own tissue.

Mesynthes has specific expertise in the biology of extracellular matrix and its role in tissue regeneration. The company has established facilities for processing of biological tissues and manufacturing medical devices to international standards.

Website: http://www.mesynthes.com/

The company profiled is one of the investment opportunities currently available in New Zealand. Please note that these opportunities are not endorsed or recommended by New Zealand Trade and Enterprise (NZTE) and may be updated from time to time. Investors are advised to contact our New Zealand-based Investment Specialist to discuss further and to conduct their own due diligence and independent advice on the relevant investment, before committing to any investment.